

**ASTRAZENECA PHARMA INDIA LIMITED**  
 Regd. Office 'Avilakkar' Off Bellary Road, Hebbal, Bangalore 560 024

**FINANCIAL RESULTS FOR THE  
 QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2011**

Sl No.	Particulars	Rs in lakhs (except for number of shares)					
		3 months ended 31.12.2011  (Unaudited)	3 months ended 30.09.2011  (Unaudited)	3 months ended 31.12.2010  (Unaudited)	Year to date figure for 9 months ended 31.12.2011  (Unaudited)	Year to date figure for 12 months ended 31.12.2010  (Unaudited)	Previous accounting year (15 months period) ended 31.03.2011  (Audited)
1	(a) Net sales (net of excise duty)	14,516.55	14,201.37	12,845.04	41,659.74	45,105.73	57,436.20
	(b) Other operating incomes: - Service income	831.75	661.06	407.25	2,299.25	1,629.09	1,966.30
2	Expenditure						
	(a) (Increase)/ decrease in stock-in-trade and work-in-progress	(1,941.87)	(93.05)	(838.16)	(3,426.54)	(1,239.17)	(1,738.95)
	(b) Consumption of raw materials and packing materials	1,349.33	1,993.81	1,602.63	5,742.23	5,963.96	7,604.40
	(c) Purchase of finished goods	5,320.28	2,620.13	3,175.12	11,088.85	9,262.29	11,681.17
	(d) Employees cost	3,523.09	3,523.44	2,542.19	10,400.15	11,220.15	15,049.76
	(e) Depreciation	188.81	191.28	185.37	552.83	705.65	881.28
	(f) Other expenditure	4,859.03	3,639.80	2,458.99	12,226.29	12,855.72	16,074.40
	(g) Total	13,298.67	11,875.41	9,126.14	36,583.81	38,748.60	49,932.15
3	Profit from operations before other income, interest & exceptional items (1-2)	2,049.66	2,987.02	4,126.15	7,375.18	7,986.22	9,478.35
4	Other incomes	150.32	145.39	153.32	445.98	408.35	628.14
5	Profit before interest & exceptional items (3+4)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
6	Interest	-	-	-	-	-	-
7	Profit after interest but before exceptional items (5-6)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
10	Tax expense	706.24	1,024.01	1,447.31	2,544.20	2,816.99	3,685.52
11	Net profit from ordinary activities after tax (9-10)	1,493.74	2,108.40	2,832.16	5,276.96	5,577.58	6,412.97
12	Extraordinary item	-	-	-	-	-	-
13	Net profit for the period (11-12)	1,493.74	2,108.40	2,832.16	5,276.96	5,577.58	6,412.97
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	-	-	-	-	-	17,468.96
16	Basic and diluted earnings (Rs) per share (not annualised)	5.97	8.43	11.33	21.11	22.31	25.65
17	Public shareholding - Number of shares - Percentage of shareholding	2,500,050 10.0002%	2,500,050 10.0002%	2,500,050 10.0002%	2,500,050 10.0002%	2,500,050 10.0002%	2,500,050 10.0002%
18	Promoters and promoter group shareholding a) Pledged/Encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the Company)	- - -	- - -	- - -	- - -	- - -	- - -
	b) Non-encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the Company)	22,499,950 100% 89.9998%	22,499,950 100% 89.9998%	22,499,950 100% 89.9998%	22,499,950 100% 89.9998%	22,499,950 100% 89.9998%	22,499,950 100% 89.9998%

## Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 2 February 2012.
- Status of investor complaints: a) Pending as on 1 October 2011 - NIL b) Received during the quarter - 1 c) Disposed off during the quarter - 1 d) Pending as on 31 December 2011 - NIL.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April- March". The financial accounts and annual report for the year ended 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 31 December 2011 are for a 9 months period, while the corresponding figures are for a 12 months period and hence not strictly comparable.
- The Company's sole reportable business segment is "Healthcare". The other segments are not material and are hence disclosed as "Others". Others comprise service income pertaining to clinical trials and co-promotion activities.
- The above statement of financial results have been subjected to limited review by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors  
 For AstraZeneca Pharma India Limited

  
 Anandh Balasundaram  
 Managing Director

Hangalore  
 Dated: 2 February 2012

**ASTRAZENECA PHARMA INDIA LIMITED**  
 Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

**SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED**

Sl No.	Particulars	Rs. in lakhs					
		3 months ended 31.12.2011 (Unaudited)	3 months ended 30.9.2011 (Unaudited)	3 months ended 31.12.2010 (Unaudited)	Year to date figure for 9 months ended 31.12.2011 (Unaudited)	12 months ended 31.12.2010 (Unaudited)	Previous accounting year (15 months period) ended 31.03.2011 (Audited)
1	Segment revenue						
	(a) Healthcare	14,520.44	14,205.80	12,850.94	41,674.10	45,128.21	57,464.43
	(b) Others	831.78	661.06	407.25	2,299.25	1,629.09	1,966.30
	Total	15,352.22	14,866.86	13,258.19	43,973.35	46,757.30	59,430.73
	Less: Inter-segment Revenue						
	Net income from operations	15,352.22	14,866.86	13,258.19	43,973.35	46,757.30	59,430.73
2	Segment results						
	Profit before tax and interest						
	(a) Healthcare	2,047.28	2,923.52	4,077.58	7,287.85	7,847.06	9,386.50
	(b) Others	6.27	67.93	54.47	101.68	161.64	112.08
Total	2,053.55	2,991.45	4,132.05	7,389.53	8,008.70	9,498.58	
	Add: Other income	146.43	140.96	147.42	431.63	385.87	599.91
	Less: Interest						
	Total profit before tax	2,199.98	3,132.41	4,279.47	7,821.16	8,394.57	10,098.49
3	Capital employed						
	(a) Healthcare	15,527.13	14,973.36	10,499.73	15,527.13	10,499.73	12,122.33
	(b) Others	562.23	463.97	24.65	562.23	24.65	644.20
	(c) Unallocated	7,156.55	6,314.85	9,514.67	7,156.55	9,514.67	5,202.43
Total	23,245.91	21,752.18	20,039.05	23,245.91	20,039.05	17,968.96	

**Notes :**

1 Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

2 The Board of Directors at their meeting held on 23 February 2010 have approved the change in the Company's statutory accounting year from "January-December" to "April-March". The financial accounts and annual report for the year ended 31 March 2011 was for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011. Accordingly, the year to date figures for the current period ended 31 December 2011 are for a 9 months period, while the corresponding figures are for a 12 months period and hence not strictly comparable.




**BSR & Co.**

(Registered)

Chartered Accountants

Maruthi Info-Tech Centre  
11-12/1 Inner Ring Road  
Koramangala  
Bangalore 560 071 India

Telephone +91 80 3980 6000  
Fax +91 80 3980 6999


**Review report to the Board of Directors of AstraZeneca Pharma India Limited**

We have reviewed the accompanying statement of unaudited financial results of AstraZeneca Pharma India Limited ("the Company") for the period ended 31 December 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for BSR & Co.  
Chartered Accountants  
Firm Registration Number: 101248W



Zubin Shekary  
Partner

Membership Number: 048814

Place: Bangalore  
Date: 2 February 2012